Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Brian J Capaldo"'
Autor:
Brian J Capaldo, Devin Roller, Mark J Axelrod, Alex F Koeppel, Emanuel F Petricoin, Craig L Slingluff, Michael J Weber, Aaron J Mackey, Daniel Gioeli, Stefan Bekiranov
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0138210 (2015)
Fifty percent of cutaneous melanomas are driven by activated BRAFV600E, but tumors treated with RAF inhibitors, even when they respond dramatically, rapidly adapt and develop resistance. Thus, there is a pressing need to identify the major mechanisms
Externí odkaz:
https://doaj.org/article/961cab1c45ad41c99b460cd723f70e2f
Autor:
Peter Balogh, Emmalee R. Adelman, John V. Pluvinage, Brian J. Capaldo, Katie C. Freeman, Sandeep Singh, Kamaleldin E. Elagib, Yukio Nakamura, Ryo Kurita, Goro Sashida, Eli R. Zunder, Hui Li, Alejandro A. Gru, Elizabeth A. Price, Stanley L. Schrier, Irving L. Weissman, Maria E. Figueroa, Wendy W. Pang, Adam N. Goldfarb
Publikováno v:
Haematologica, Vol 105, Iss 4 (2020)
Healthy bone marrow progenitors yield a co-ordinated balance of hematopoietic lineages. This balance shifts with aging toward enhanced granulopoiesis with diminished erythropoiesis and lymphopoiesis, changes which likely contribute to the development
Externí odkaz:
https://doaj.org/article/140cf8159011466eac9107c51977f0f3
Autor:
Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
Publikováno v:
Blood Advances, Vol 1, Iss 14, Pp 933-946 (2017)
Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable response
Externí odkaz:
https://doaj.org/article/8971b2c6746d4ca78045d1f18e8e94de
Autor:
Daniel Gioeli, Michael J. Weber, Aaron Mackey, Karin Jensen, Brian J. Capaldo, Mark Axelrod, Devin G. Roller
Recent data show that extracellular signals are transmitted through a network of proteins rather than hierarchical signaling pathways, suggesting that the inhibition of a single component of a canonical pathway is insufficient for the treatment of ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5132c624f0ec19884130743959be8825
https://doi.org/10.1158/1535-7163.c.6535764.v1
https://doi.org/10.1158/1535-7163.c.6535764.v1
Autor:
Daniel Gioeli, Michael J. Weber, Aaron Mackey, Karin Jensen, Brian J. Capaldo, Mark Axelrod, Devin G. Roller
PDF file, 428K, The combination of sorafenib and diclofenac causes cell death.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02b556e5ee766cee90e16befefbf6aad
https://doi.org/10.1158/1535-7163.22497999
https://doi.org/10.1158/1535-7163.22497999
Autor:
Nichelle C. Whitlock, Margaret E. White, Brian J. Capaldo, Anson T. Ku, Supreet Agarwal, Lei Fang, Scott Wilkinson, Shana Y. Trostel, Zhen-Dan Shi, Falguni Basuli, Karen Wong, Elaine M. Jagoda, Kathleen Kelly, Peter L. Choyke, Adam G. Sowalsky
Publikováno v:
Discover Oncology. 13
Background The activities of MYC, the androgen receptor, and its associated pioneer factors demonstrate substantial reprogramming between early and advanced prostate cancer. Although previous studies have shown a shift in cellular metabolic requireme
Autor:
Supreet Agarwal, Lei Fang, Kerry McGowen, JuanJuan Yin, Joel Bowman, Anson T. Ku, Aian Neil Alilin, Eva Corey, Martine Roudier, Lawrence True, Ruthy Dumpit, Ilsa Coleman, John Lee, Peter S. Nelson, Brian J. Capaldo, Aida Mariani, Clare Hoover, Ilya S. Senatorov, Michael Beshiri, Adam G. Sowalsky, Elaine M Hurt, Kathleen Kelly
Antibody-drug conjugates (ADCs) are promising targeted cancer therapy; however, patient selection based solely on target antigen expression without consideration for cytotoxic payload vulnerabilities has plateaued clinical benefits. Biomarkers to cap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4030e1e3956b208358fef55ddf9350c5
https://doi.org/10.1101/2022.04.19.488784
https://doi.org/10.1101/2022.04.19.488784
Autor:
Michael L. Beshiri, Brian J. Capaldo, Ross Lake, Anson T. Ku, Danielle Burner, Caitlin M. Tice, Crystal Tran, Julianna Kostas, Aian Neil Alilin, JuanJuan Yin, Supreet Agarwal, Samantha A. Morris, Fatima H. Karzai, Tamara L. Lotan, William L. Dahut, Adam G. Sowalsky, Kathleen Kelly
SUMMARYTo resist lineage-dependent therapies, cancer cells adopt a plastic stem-like state, leading to phenotypic heterogeneity. Here we dissect the cellular origins of such heterogeneity in a metastatic castration-resistant prostate cancer (CRPC) pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35ec822d77262605fc0fe2c8e9d5dacf
https://doi.org/10.1101/2022.03.24.484651
https://doi.org/10.1101/2022.03.24.484651
Autor:
Rayann Atway, Huihui Ye, Elizabeth D. Walton, Nicole V. Carrabba, S. Thomas Hennigan, Nicholas T. Terrigino, Nichelle C. Whitlock, Brian J. Capaldo, Ross Lake, Shana Y. Trostel, Adam G. Sowalsky, Scott Wilkinson, Berkley E. Gryder
Publikováno v:
Oncogene
Localized prostate cancer develops very slowly in most men, with the androgen receptor (AR) and MYC transcription factors amongst the most well-characterized drivers of prostate tumorigenesis. Canonically, MYC up-regulation in luminal prostate cancer